Xtacy Therapeutics (TSE:XTCY) has released an update.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Xtacy Therapeutics Corp. has announced changes to its Board of Directors, with Vanni Barbon joining as a Director and the new Audit Chair, bringing a wealth of experience in banking and public markets. The company expressed gratitude to Ashleigh Vogstad for her service as she steps down, and CEO Meris Kott anticipates continued advice from her. Xtacy Therapeutics focuses on wellness consumer products, including psychedelics and healthcare-related targets.
For further insights into TSE:XTCY stock, check out TipRanks’ Stock Analysis page.
Trending Articles:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue